Resveratrol and its impact on aging and thyroid function

Journal of Endocrinological Investigation

Volumn 34, Issue 10, 2011, Pages 788-792

  Duntas, L H ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Resveratrol; Sirtuins; The French paradox; Thyroid; Thyroid cancer

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; QUERCETIN; RESVERATROL; SIRTUIN 1; THIAMAZOLE; THYROTROPIN;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; DIET SUPPLEMENTATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE METABOLISM; GRAVES DISEASE; HUMAN; LIPID METABOLISM; REVIEW; THYROID FOLLICULAR CARCINOMA; THYROID FUNCTION; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; AGING; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; THYROID GLAND; THYROID NEOPLASMS; THYROTROPIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856816295     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7926     Document Type: Review

References (54)

1. Takaoka M. Resveratrol, a new phenolic compound, from veratrum grandiflorum. Nippon Kagaku Kaishi 1939, 60: 1090-100.
2. Hathway DE, Seakins JWT. Hydroxystilbenes of Eucalyptus wandoo. Biochem J 1959, 72: 369-74.
3. Delaunois B, Cordelier S, Conreux A, Clément C, Jeandet P. Molecular engineering of resveratrol in plants. Plant Biotechnol J 2009, 7: 2-12.
4. Das M, Das DK. Resveratrol and cardiovascular health. Mol Aspects Med 2010, 31: 503-12.
5. Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox". Semin Thromb Hemost 2010, 36: 59-70.
6. Pineda-Sanabria SE, Robertson IM, Sykes BD. Structure of transresveratrol in complex with the cardiac regulatory protein troponin C. Biochemistry 2011, 50: 1309-20.
7. Vitaglione P, Sforza S, Galaverna G, et al. Bioavailability of transresveratrol from red wine in humans. Mol Nutr Food Res 2005, 49: 495-504. (Pubitemid 40780396)
8. Berrougui H, Grenier G, Loued S, Drouin G, Khalil A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 2009, 20: 420-7.
9. Ghanim H, Sia CL, Korzeniewski K, et al. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab 2011, 96): 1409-14.
10. Sebai H, Hovsépian S, Ristorcelli E, Aouani E, Lombardo D, Fayet G. Resveratrol increases iodide trapping in the rat thyroid cell line FRTL-5. Thyroid 2010, 20: 195-203.
11. Renaud S, Gueguen R. The French paradox and wine drinking. Novartis Found Symp 1998, 216: 208-17.
12. Maxwell S, Cruickshank A, Thorpe G. Red wine and antioxidant activity in serum. Lancet 1994, 344: 193-4. (Pubitemid 24218896)
13. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339: 1523-6.
14. Corder R, Mullen W, Khan NQ, et al. Oenology: red wine procyanidin and vascular health. Nature 2006, 444: 566. (Pubitemid 44864428)
15. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995, 235: 207-19.
16. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet 1993, 341: 1103-4. (Pubitemid 23114451)
17. Wu JM, Hsieh TC. Resveratrol: a cardioprotective substance. Ann N Y Acad Sci 2011, 1215: 16-21.
18. Pendurthi UR, Williams JT, Rao LV. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler Thromb Vasc Biol 1999, 19: 419-26. (Pubitemid 29072759)
19. Sun AY, Wang Q, Simonyi A, Sun GY. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 2010, 41: 375-83.
20. Kampa M, Hatzoglou A, Notas G, et al. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 2000, 37: 223-33.
21. Lanz T, Tropf S, Marner FJ, Schröder J, Schröder G. The role of cysteines in polyketide synthases. Site-directed mutagenesis of resveratrol and chalcone synthases, two key enzymes in different plant-specific pathways. J Biol Chem 1991, 266: 9971-6. (Pubitemid 21906750)
22. Tropf S, Lanz T, Rensing SA, Schröder J, Schröder G. Evidence that Silibene synthases have developed from chalcone synthases several times in the course of evolution. J Mol Evolution 1994, 38: 610-8. (Pubitemid 24177294)
23. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci 2011, 1215: 9-15.
24. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32: 1377-82. (Pubitemid 39564557)
25. Vaz-da-Silva M, Loureiro AI, Falcao A, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther 2008, 46: 564-70.
26. Orallo F. Trans-resveratrol: a magical elixir of eternal youth? Curr Med Chem 2008, 15: 1887-98.
27. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability and metabolic profile of resveratrol and its dimethylether analog, pterostilbene in rats. Cancer Chemother Pharmacol 2011, 68: 593-601.
28. Knutson MD, Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev 2008, 66: 591-6.
29. Bass TM, Weinkove D, Houthoofd K, Gems D, Partridge L. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech Ageing Dev 2007, 128: 546-52. (Pubitemid 47498522)
30. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J. Sirtuins: the "magnificent seven", function, metabolism and longevity. Ann Med 2007, 39: 335-45.
31. Kyrylenko S, Baniahmad A. Sirtuin family: a link to metabolic signaling and senescence. Curr Med Chem 2010, 17: 2921-32.
32. Lomb DJ, Laurent G, Haigis MC. Sirtuins regulate key aspects of lipid metabolism. Biochim Biophys Acta 2010, 1804: 1652-7.
33. Ghosh HS. The anti-aging, metabolism potential of SIRT1. Curr Opin Investig Drugs 2008, 9: 1095-102.
34. Alcaín FJ, Villalba JM. Sirtuin activators. Expert Opin Ther Pat 2009, 19: 403-14.
35. Costa Cdos S, Rohden F, Hammes TO, et al. Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARγ1-3 mRNA expression in human visceral adipocytes. Obes Surg 2011, 21: 356-61.
36. Barger JL, Kayo T, Vann JM, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008, 3: e2264.
37. Agarwal B, Baur JA. Resveratrol and life extension. Ann N Y Acad Sci 2011, 1215: 138-43.
38. Petrovski G, Gurusamy N, Das DK. Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 2011, 1215: 22-33.
39. Camins A, Sureda FX, Junyent F, et al. Sirtuin activators: designing molecules to extend life span. Biochem Biophys Acta 2010, 1799: 740-9.
40. Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin resistant conditions by repressing PTPIB. Cell Metab 2007, 6: 307-19. (Pubitemid 47468091)
41. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450: 712-6. (Pubitemid 350207685)
42. Shih A, Davis FB, Lin HY, Davis PJ. Resveratrol induces apoptosis in thyroid cancer cell lines via a MARK-and p53 dependent mechanism. J Clin Endocrinol Metab 2002, 87: 1223-32. (Pubitemid 36121092)
43. Shih A, Lin H-Y, Davis FB, Davis PJ. Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry 2001, 40: 2870-8. (Pubitemid 32198289)
44. She QB, Chen N, Dong Z. ERKs and p38 kinase phosphorylation p53 protein at serine 15 in response to UV radiation. J Biol Chem 2000, 275: 20444-9. (Pubitemid 30457622)
45. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domain of p21 involved in the inhibition of cdk kinase and PCA. Nature 1995, 374: 386-8.
46. Böttner M, Christoffel J, Rimoldi G, Wuttke W. Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on the pituitary-thyroid-axis. Exp Clin Endocrinol Diabetes 2006, 114: 82-90.
47. da-Silva WS, Harney JW, Kim BW, et al. The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes 2007, 56: 767-76. (Pubitemid 46348481)
48. Akieda-Asai S, Zaima N, Ikegami K, et al. SIRT1 regulates thyroid-stimulating hormone release by enhancing PIP5Kc activity through deacetylation of specific lysine residues in mammals. PLoS One 2010, 5: e11755.
49. Fullerton MD, Steinberg GR. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. Diabetes 2010, 59: 551-3.
50. Morris JC. Resveratrol, thyroid cancer, and iodide: drink up? Thyroid 2010, 20: 125-6.
51. Boue SM, Cleveland TE, Carter-Wientjes C, et al. Phytoalexin-enriched functional foods. J Agric Food Chem 2009, 57: 2614-22.
52. Fischer-Posovszky P, Kukulus V, Tews D, et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr 2010, 92: 5-15.
53. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci 2011, 1215: 161-9.
54. Mukherjee S, Ray D, Lekli I, Bak I, Tosaki A, Das DK. Effects of Longevinex (modified resveratrol) on cardioprotection and its mechanisms of action. Can J Physiol Pharmacol 2010, 88: 1017-25.